Limits...
Salvianolic acid A as a multifunctional agent ameliorates doxorubicin-induced nephropathy in rats.

Fan HY, Yang MY, Qi D, Zhang ZK, Zhu L, Shang-Guan XX, Liu K, Xu H, Che X - Sci Rep (2015)

Bottom Line: Evidence suggest that multidrug therapy has more effect than monotherapy in amelioration of renal injury.Results revealed that treatment with SAA alleviated histological damages, relieved proteinuria, hypoalbuminemia and hyperlipidemia, reduced oxidative stress, as well as improving hemorheology.The anti-inflammation, antioxidant, amelioration of podocyte injury, improvement of hemorheology and hypolipidemic properties may constituent an important part of its therapeutic effects.

View Article: PubMed Central - PubMed

Affiliation: School of Pharmacy, Yantai University, 264005 Yantai, Shandong Province, China.

ABSTRACT
Nephrotic syndrome (NS) is still a therapeutic challenge. To date there is no ideal treatment. Evidence suggest that multidrug therapy has more effect than monotherapy in amelioration of renal injury. Salvianolic acid A (SAA) is the major active component of Salviae Miltiorrhizae Bunge. Previous studies have demonstrated that SAA is a multi-target agent and has various pharmacological activities. The pleiotropic properties of SAA predict its potential in the treatment of NS. The study investigated the effect of SAA on doxorubicin-induced nephropathy. The kidney function related-biochemical changes, hemorheological parameters and oxidative stress status were determined, and histological examination using light and transmission electron microcopies and western blot analysis were also performed. Results revealed that treatment with SAA alleviated histological damages, relieved proteinuria, hypoalbuminemia and hyperlipidemia, reduced oxidative stress, as well as improving hemorheology. Furthermore, SAA restored podocin expression, down-regulated the expression of NF-κB p65 and p-IκBα while up-regulating IκBα protein expression. Overall, as a multifunctional agent, SAA has a favorable renoprotection in doxorubicin-induced nephropathy. The anti-inflammation, antioxidant, amelioration of podocyte injury, improvement of hemorheology and hypolipidemic properties may constituent an important part of its therapeutic effects. All these indicate that SAA is likely to be a promising agent for NS.

No MeSH data available.


Related in: MedlinePlus

Treatment with SAA ameliorated podocyte foot process effacement in doxorubicin-induced nephropathy rats.Rats were treated as described in the legend of Fig. 1. At the end of the experiment, rats were sacrificed and renal tissue were dissected and fixed for electron microscopic examination. Scale bar, 1 μm or 2 μm. Abbreviations: SAA, Salvianolic acid A; DOX, Doxorubicin.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4508635&req=5

f4: Treatment with SAA ameliorated podocyte foot process effacement in doxorubicin-induced nephropathy rats.Rats were treated as described in the legend of Fig. 1. At the end of the experiment, rats were sacrificed and renal tissue were dissected and fixed for electron microscopic examination. Scale bar, 1 μm or 2 μm. Abbreviations: SAA, Salvianolic acid A; DOX, Doxorubicin.

Mentions: Transmission electron microscopic examination was performed to analyze the ultrastructural changes in renal tissue. There were no apparent damages as evaluated by intactness of glomerulus and tubules in renal tissues of control rats. The foot processes were clearly observed, and there was no swelling and hypertrophy. In DOX-treated rats, the basal structure of glomerulus was damaged, which manifested as extensive fusion and effacement of foot processes and mild thickening of glomerular basement membrane (GBM). In renal tissues of rats treated with prednisone acetate and SAA, only focal segmental podocyte foot process fusion and effacement were observed. These results suggested that SAA could protect podocyte from damage caused by DOX (Fig. 4).


Salvianolic acid A as a multifunctional agent ameliorates doxorubicin-induced nephropathy in rats.

Fan HY, Yang MY, Qi D, Zhang ZK, Zhu L, Shang-Guan XX, Liu K, Xu H, Che X - Sci Rep (2015)

Treatment with SAA ameliorated podocyte foot process effacement in doxorubicin-induced nephropathy rats.Rats were treated as described in the legend of Fig. 1. At the end of the experiment, rats were sacrificed and renal tissue were dissected and fixed for electron microscopic examination. Scale bar, 1 μm or 2 μm. Abbreviations: SAA, Salvianolic acid A; DOX, Doxorubicin.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4508635&req=5

f4: Treatment with SAA ameliorated podocyte foot process effacement in doxorubicin-induced nephropathy rats.Rats were treated as described in the legend of Fig. 1. At the end of the experiment, rats were sacrificed and renal tissue were dissected and fixed for electron microscopic examination. Scale bar, 1 μm or 2 μm. Abbreviations: SAA, Salvianolic acid A; DOX, Doxorubicin.
Mentions: Transmission electron microscopic examination was performed to analyze the ultrastructural changes in renal tissue. There were no apparent damages as evaluated by intactness of glomerulus and tubules in renal tissues of control rats. The foot processes were clearly observed, and there was no swelling and hypertrophy. In DOX-treated rats, the basal structure of glomerulus was damaged, which manifested as extensive fusion and effacement of foot processes and mild thickening of glomerular basement membrane (GBM). In renal tissues of rats treated with prednisone acetate and SAA, only focal segmental podocyte foot process fusion and effacement were observed. These results suggested that SAA could protect podocyte from damage caused by DOX (Fig. 4).

Bottom Line: Evidence suggest that multidrug therapy has more effect than monotherapy in amelioration of renal injury.Results revealed that treatment with SAA alleviated histological damages, relieved proteinuria, hypoalbuminemia and hyperlipidemia, reduced oxidative stress, as well as improving hemorheology.The anti-inflammation, antioxidant, amelioration of podocyte injury, improvement of hemorheology and hypolipidemic properties may constituent an important part of its therapeutic effects.

View Article: PubMed Central - PubMed

Affiliation: School of Pharmacy, Yantai University, 264005 Yantai, Shandong Province, China.

ABSTRACT
Nephrotic syndrome (NS) is still a therapeutic challenge. To date there is no ideal treatment. Evidence suggest that multidrug therapy has more effect than monotherapy in amelioration of renal injury. Salvianolic acid A (SAA) is the major active component of Salviae Miltiorrhizae Bunge. Previous studies have demonstrated that SAA is a multi-target agent and has various pharmacological activities. The pleiotropic properties of SAA predict its potential in the treatment of NS. The study investigated the effect of SAA on doxorubicin-induced nephropathy. The kidney function related-biochemical changes, hemorheological parameters and oxidative stress status were determined, and histological examination using light and transmission electron microcopies and western blot analysis were also performed. Results revealed that treatment with SAA alleviated histological damages, relieved proteinuria, hypoalbuminemia and hyperlipidemia, reduced oxidative stress, as well as improving hemorheology. Furthermore, SAA restored podocin expression, down-regulated the expression of NF-κB p65 and p-IκBα while up-regulating IκBα protein expression. Overall, as a multifunctional agent, SAA has a favorable renoprotection in doxorubicin-induced nephropathy. The anti-inflammation, antioxidant, amelioration of podocyte injury, improvement of hemorheology and hypolipidemic properties may constituent an important part of its therapeutic effects. All these indicate that SAA is likely to be a promising agent for NS.

No MeSH data available.


Related in: MedlinePlus